(11) 98705-3426
TrademarkIQ iconTrademarkIQ
Back to search
Official data from USPTO

RILFAVY

Did you know this trademark is already registered in United States?

Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.

Active USPTO registrationType: WordOffice: United States

Quick snapshot

RILFAVY

ST13

US500000079221473

Class

5

Filing

79221473

Registration

5435742

Risk and opportunity diagnosis

Executive reading for naming, filing, and monitoring decisions.

USPTO status

Active USPTO registration

Case type

Application and registration

Recorded events

21

Latest update

12/06/2025

Trademark type

Word

Nice classes

5

Filing date

08/30/2017

Registration date

04/03/2018

Expiration date

-

Complete case details

Structured fields from the responsible authority and the official record.

Status date

10/18/2024

Last transaction

12/06/2025

Responsible office

United States Patent and Trademark Office

Status code

709

Official register

Principal Register

Drawing code

4

Owner type

25

Owner location

CH

Examiner

PODESTA,GIDETTE

Law office

N70

Current location

PUBLICATION AND ISSUE SECTION

Holders and representatives

Holders

NOVARTIS AG

Representatives

Novartis Pharma AG, Trademark Department

Technical classification

Nice Classes

Class 5

Vienna Codes

No Vienna codes available.

Goods and services

Class 5

Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastrointestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune systemthe metabolic systemthe endocrine systemthe musculoskeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for ophthalmological use; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and the treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthma

Publications

History of USPTO decisions and trademark events.

21 publications found

INNT

TOTAL INVALIDATION PROCESSED BY THE IB

12/05/2025

INTS

TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB

11/18/2025

INPC

INVALIDATION PROCESSED

11/18/2025

INTR

TOTAL INVALIDATION OF REG EXT PROTECTION CREATED

06/18/2025

C71T

CANCELLED SECTION 71

10/18/2024

GPNX

NOTIFICATION PROCESSED BY IB

05/25/2018

FICS

FINAL DISPOSITION NOTICE SENT TO IB

05/08/2018

FIMP

FINAL DISPOSITION PROCESSED

05/08/2018

GPAR

GRANT OF PROTECTION CREATED, TO BE SENT TO IB

05/03/2018

R.PR

REGISTERED-PRINCIPAL REGISTER

04/03/2018

GPNX

NOTIFICATION PROCESSED BY IB

01/27/2018

PUBO

PUBLISHED FOR OPPOSITION

01/16/2018

OPNS

NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB

01/10/2018

OP2R

NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB

01/10/2018

NPUB

NOTICE OF PUBLICATION

12/27/2017

MAFR

APPLICATION FILING RECEIPT MAILED

12/09/2017

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

12/08/2017

DOCK

ASSIGNED TO EXAMINER

12/05/2017

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

12/05/2017

LIMI

LIMITATION FROM ORIGINAL APPLICATION ENTERED

11/30/2017

REPR

SN ASSIGNED FOR SECT 66A APPL FROM IB

11/23/2017

Continuous trademark protection

Get notified about every new filing that threatens RILFAVY or your mark.

Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.